Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001328143-19-000026
Filing Date
2019-05-09
Accepted
2019-05-09 16:02:55
Documents
64
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q adms10q3312019.htm 10-Q 1055859
2 EXHIBIT 31.1 adms10qq12019ex311.htm EX-31.1 14288
3 EXHIBIT 31.2 adms10qq12019ex312.htm EX-31.2 14400
4 EXHIBIT 32.1 adms10qq12019ex321.htm EX-32.1 9280
  Complete submission text file 0001328143-19-000026.txt   4754469

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT adms-20190331.xml EX-101.INS 898084
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adms-20190331.xsd EX-101.SCH 37468
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT adms-20190331_cal.xml EX-101.CAL 70898
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT adms-20190331_def.xml EX-101.DEF 172409
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adms-20190331_lab.xml EX-101.LAB 496561
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adms-20190331_pre.xml EX-101.PRE 281446
Mailing Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

EIN.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36399 | Film No.: 19810406
SIC: 2834 Pharmaceutical Preparations